<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382094</url>
  </required_header>
  <id_info>
    <org_study_id>RCT-PC-QLS 2004</org_study_id>
    <nct_id>NCT02382094</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III clinical trial to study quality of life in prostate cancer patients by randomizing&#xD;
      anti-androgen versus total androgen blockage prior to curative intended radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To study the difference in quality of life in relation to anti-androgen&#xD;
      versus total androgen blockage.&#xD;
&#xD;
      Exploratory parameters: ▪ Time to PSA relapse&#xD;
&#xD;
        -  Time to symptom giving metastasis&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
      Patients with localized /locally advanced prostate cancer were subject to treatment with&#xD;
      curative intention. They could be divided into three groups according to the risk of&#xD;
      metastasis. Mainly intermediate risk group of patients were included in this study. Patients&#xD;
      with low risk could be included if they were subject to neo-adjuvant hormonal therapy.&#xD;
      Different risk groups were defined as below:&#xD;
&#xD;
      Low risk group: PSA ≤10 ng/ml Gleason score ≤ 6 Tumour stage ≤ T2b Intermediate risk group:&#xD;
      Presence of 1-2 factors of high risk. High risk group: PSA &gt;10 ng/ml Gleason score ≥7 Tumour&#xD;
      stage T2c - T3b&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA relapse</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptom giving metastasis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm AA(anti-androgen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bicalutamide 150 mg per os daily + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm TAB (Total androgen blockade)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bicalutamide 50 mg orally daily + Goserelin 3.6 mg subcutaneously every 28±2 days + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <arm_group_label>Arm AA(anti-androgen)</arm_group_label>
    <arm_group_label>Arm TAB (Total androgen blockade)</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Histopathologically verified prostatic adenocarcinoma.&#xD;
&#xD;
          2. All consecutive patients referred for radiation therapy with combination method i.e.&#xD;
             both external beam RT and HDR brachytherapy or other fractionation with curative&#xD;
             intention.&#xD;
&#xD;
          3. Patients with intermediate risk group of prostate cancer will mainly be included in&#xD;
             this study where radiotherapy with intention to cure is indicated and possible to&#xD;
             perform. The intermediate risk group is defined as having 1-2 high risk factors for&#xD;
             metastasis. Patients with low risk can only be possible to include if there is an&#xD;
             indication of neo-adjuvant hormonal therapy.&#xD;
&#xD;
          4. No signs of distant metastasis.&#xD;
&#xD;
          5. Informed consent.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure to fulfill inclusion criteria.&#xD;
&#xD;
          2. Severe hepatic or renal failure, according to clinical and laboratory examinations,&#xD;
             serum creatinine &gt; 225 mmol/l.&#xD;
&#xD;
          3. Concomitant diseases that would influence the planned treatment (e.g. Inflammatory&#xD;
             bowel disease, urinary incontinence, severe atherosclerosis, myocardial infarction&#xD;
             within last 6 months.&#xD;
&#xD;
          4. Previous diagnosis of other malignant diseases excluding patients who are free from&#xD;
             relapse after at least 5 years of diagnosis. Patients with basal cell carcinoma are&#xD;
             includable.&#xD;
&#xD;
          5. Inability of the patient to cope with the study rules, due to abuses, mentalstatus or&#xD;
             other reasons&#xD;
&#xD;
          6. Participation in other clinical studies at the same time if it considers may hamper&#xD;
             the assessment of QoL.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>khairul Majumder</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>curative intention</keyword>
  <keyword>radiation Therapy</keyword>
  <keyword>health related quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

